The Biocodex Group Strengthens Its Position in Microbiota
The Biocodex Microbiota Foundation is looking for academics and scientists in Canada to apply for a €25,000 research grant aimed at helping advance the study of the gut microbiome MONTREAL, July 31,...
Biocodex Group Strengthens Its Position in the US Market With the Acquisition of Hilma, a Fast-Growing Natural Remedies Start-Up
SAN MATEO, Calif., Sept. 21, 2022 /PRNewswire/ -- Biocodex, Inc., a pharmaceutical company and manufacturer of DIACOMIT® (stiripentol), announced today that the U.S. Food and Drug Administration (FDA) has approved DIACOMIT for the treatment of seizures associated with Dravet syndrome in patients 6 months and older, weighing 15 lb or more, and taking clobazam.1 The antiseizure treatment first received FDA approval in 2018 for children 2 years and older.
PANTHERx Rare announces that it has been selected by Biocodex as their new exclusive U.S. pharmacy distribution partner for DIACOMIT® (stiripentol)....
MEXICO CITY, Sept. 14, 2021 /PRNewswire/ -- m8 Pharmaceuticals and Biocodex have signed an exclusive licensing agreement for the Mexican and Brazilian market for Diacomit® (stiripentol). Diacomit® is approved for adjunctive treatment with clobazam and valproate in Dravet syndrome in over 27 countries, including North America and Europe. Dravet syndrome, also known as severe myoclonic epilepsy in infancy (SMEI), is a catastrophic early onset epileptic syndrome that is thought to affect approximately 1,000 to 2,000 patients in Mexico, and approximately 2,000 to 4,000 patients in Brazil. In most cases, the first seizures occur during the first year of life. Dravet syndrome is characterized by severe epilepsy, psychomotor retardation, and often ataxia. Status epilepticus is frequent and is thought to be in part responsible for the high premature mortality rate reported in these patients, ranging from 15.9 to 18%.
Encoded Therapeutics reeled in $104 million in series C cash to bankroll the development of its lead program: a precision gene therapy for Dravet syndrome, a rare form of epilepsy. The Bay Area biotech will also use the funds to push its preclinical programs and come up with new treatments for severe genetic disorders.
Neurim Pharmaceuticals ('Neurim') announced today that it has entered into a licensing agreement with Biocodex. The agreement grants Biocodex exclusive marketing rights for Neurim's new Rx PedPRM in France.nnNeurim's age-appropriate drug is targeted to treat sleep disorders in children with autism spectrum disorders (ASD) and neurogenetic diseases. It is expected to be the first sleep drug approved for children.
Production has begun at a BASF facility in Germany to help feed the growth in pharma demand for specialty amines.
Shares of Dr Reddy's gained nearly 1 per cent on Wednesday morning to Rs 4,353 after the company informed BSE that it has signed a strategic alliance with Biocodex to market and distribute the latter's flagship products in Romania.